指南与共识甲状腺疾病

2015年ATA指南在远处转移性分化型甲状腺癌中的评估

Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
指南 / 共识 · J Clin Endocrinol Metab · 2020-01-01

该回顾性研究纳入83例初始治疗时即诊断远处转移的分化型甲状腺癌患者,并以472例无常规RAI指征患者为对照。结果显示,无常规RAI指征者中1.6%存在远处转移;转移患者中17%获极佳反应,67%在中位随访62个月后仍有结构性疾病,且极佳反应者均无复发。2015年ATA指南对持续性疾病和复发预测良好。

要点

  • 无常规RAI指征患者中1.6%存在远处转移,可能被遗漏。
  • 远处转移患者中17%达极佳反应,67%有结构性疾病。
  • 达极佳反应的远处转移患者均未复发。

核心结论

  • 按2015年ATA指南无常规RAI指征的患者中,1.6%的远处转移初始会被遗漏。
  • 在诊断时即有远处转移的患者中,2015年ATA指南对持续性疾病和复发的预测效果极佳。

研究设计与样本

  • 回顾性纳入83例初始治疗前后诊断远处转移的分化型甲状腺癌患者。
  • 对照组为472例无常规RAI指征患者,其中低危312例、中危160例。

主要发现

  • 83例远处转移患者中,14例(17%)达极佳反应,55例(67%)在中位随访62个月时有结构性疾病。
  • 14例达极佳反应的患者均未出现复发。

临床怎么用

  • 对无常规RAI指征的低中危患者,仍需警惕少数可能存在的远处转移。
  • 对已诊断远处转移的患者,可用2015年ATA危险分层预测持续性疾病和复发。

局限性

  • 为回顾性研究,样本量有限。
  • 对照组仅纳入无常规RAI指征患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Current American Thyroid Association (ATA) Management Guidelines for the treatment of differentiated thyroid cancer (DTC) stratify patients to decide on additional radioiodine (RAI) therapy after surgery, and to predict recurring/persisting disease. However, studies evaluating the detection of distant metastases and how these guidelines perform in patients with distant metastases are scarce. OBJECTIVE: To evaluate the 2015 ATA Guidelines in DTC patients with respect to 1) the detection of distant metastases, and 2) the accuracy of its Risk Stratification System in patients with distant metastases. PATIENTS AND MAIN OUTCOME MEASURES: We retrospectively included 83 DTC patients who were diagnosed with distant metastases around the time of initial therapy, and a control population of 472 patients (312 low-risk, 160 intermediate-risk) who did not have a routine indication for RAI therapy. We used the control group to assess the percentage of distant metastases that would have been missed if no RAI therapy was given. RESULTS: Two hundred forty-six patients had no routine indication for RAI therapy of which 4 (1.6%) had distant metastases. Furthermore, among the 83 patients with distant metastases, 14 patients (17%) had excellent response, while 55 (67%) had structural disease after a median follow-up of 62 months. None of the 14 patients that achieved an excellent response had a recurrence. CONCLUSIONS: In patients without a routine indication for RAI therapy according to the 2015 ATA Guidelines, distant metastases would initially have been missed in 1.6% of the patients. Furthermore, in patients with distant metastases upon diagnosis, the 2015 ATA Guidelines are an excellent predictor of both persistent disease and recurrence.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. van Velsen EFS, Stegenga MT, van Kemenade FJ, et al. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2020. PMID: 31665318. doi:10.1210/clinem/dgz137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。